Pepcid May Help Treat Chronic Heart Failure

Famotidine improves both cardiac symptoms and ventricular remodeling

TUESDAY, Sept. 26 (HealthDay News) -- Famotidine (Pepcid), the over-the-counter medication for the treatment of heartburn and acid reflux, reduces both cardiac symptoms and ventricular remodeling associated with chronic heart failure, according to a study published online Sept. 25 in the Journal of the American College of Cardiology.

To test the hypothesis that a blockade of histamine H2 receptors could be of benefit in treating chronic heart failure patients, Masafumi Kitakaze, M.D., Ph.D., of the National Cardiovascular Center in Suita, Japan, and colleagues conducted a prospective study of 50 chronic heart failure patients randomized to receive 30 mg/day of famotidine or teprenone for six months.

Those in the famotidine group had decreased New York Heart Association functional class and plasma B-type natriuretic peptide levels. This reflected decreased left ventricular end-diastolic and end-systolic lengths (LVDd and LVDs, respectively) with unaltered fractional shortening.

The authors are cautiously optimistic about their findings. "Now we need to conduct a large-scale trial to confirm the present findings," said Kitakaze in a statement. "The large-scale trial based on the results [of] our present research may not help current heart failure patients because it takes time, but we hope it helps our children and grandchildren and others in the future."

Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing